Hockin M F, Kalafatis M, Shatos M, Mann K G
College of Medicine, Department of Biochemistry, University of Vermont, Burlington 05405-0068, USA.
Arterioscler Thromb Vasc Biol. 1997 Nov;17(11):2765-75. doi: 10.1161/01.atv.17.11.2765.
The inactivation of factor Va was examined on primary cultures of human umbilical vein endothelial cells (HUVECs), either after addition of activated protein C (APC) or after addition of alpha-thrombin and protein C (PC) zymogen. Factor Va proteolysis was visualized by Western blot analysis using a monoclonal antibody (alpha HVaHC No. 17) to the factor Va heavy chain (HC), and cofactor activity was followed both in a clotting assay using factor V-deficient plasma and by quantitation of prothrombinase function. APC generation was monitored using the substrate 6-(D-VPR)amino-1-naphthalenebutylsulfonamide (D-VPR-ANSNHC4H9), which permits quantitation of APC at 10 pmol/L. Addition of APC (5 nmol/L) to an adherent HUVEC monolayer (3.5 x 10(5) cells per well) resulted in a 75% inactivation of factor Va (20 nmol/L) within 10 minutes, with complete loss of cofactor activity within 2 hours. Measurements of the rate of cleavage at Arg506 and Arg306 in the presence and absence of the HUVEC monolayer indicated that the APC-dependent cleavage of the factor Va HC at Arg506 was accelerated in the presence of HUVECs, while cleavage at Arg306 was dependent on the presence of the HUVEC surface. Factor Va inactivation proceeded with initial cleavage of the factor Va HC at Arg506, generating an M(r) 75,000 species. Further proteolysis at Arg306 generated an M(r) 30,000 product. When protein C (0.5 mumol/L), alpha-thrombin (1 nmol/L), and factor Va (20 nmol/L) were added to HUVECs an APC generation rate of 1.56 +/- 0.11 x 10(-14) mol/min per cell was observed. With APC generated in situ, cleavage at Arg506 on the HUVEC surface is followed by cleavage at Arg306, generating M(r) 75,000 and M(r) 30,000 fragments, respectively. In addition, the appearance of two novel products derived from the factor Va HC are observed when thrombin is present on the HUVEC surface: the HC is processed through limited thrombin proteolysis to generate an M(r) 97,000 fragment, which is further processed by APC to generate an M(r) 43,000 fragment. NH2-terminal sequence analysis of the M(r) 97,000 fragment revealed that the thrombin cleavage occurs in the COOH-terminus of the intact factor Va HC since both the intact HC as well as the M(r) 97,000 fragment have the same sequence. Our data demonstrate that the inactivation of factor Va on the HUVEC surface, initiated either by APC addition or PC activation, follows a mechanism whereby cleavage is observed first at Arg506 followed by a second cleavage at Arg306. The latter cleavage is dependent on the availability of the HUVEC surface. This mechanism of inactivation of factor Va is similar to that observed on synthetic phospholipid vesicles.
在人脐静脉内皮细胞(HUVECs)的原代培养物中,研究了因子Va的失活情况,分别是在添加活化蛋白C(APC)后,以及添加α-凝血酶和蛋白C(PC)酶原后。使用针对因子Va重链(HC)的单克隆抗体(αHVaHC No. 17)通过蛋白质印迹分析来观察因子Va蛋白水解情况,并在使用缺乏因子V血浆的凝血试验以及通过定量凝血酶原酶功能来跟踪辅因子活性。使用底物6-(D-VPR)氨基-1-萘丁基磺酰胺(D-VPR-ANSNHC4H9)监测APC生成情况,该底物可对10 pmol/L 的APC进行定量。向贴壁的HUVEC单层(每孔3.5 x 10(5)个细胞)中添加APC(5 nmol/L)会导致因子Va(20 nmol/L)在10分钟内失活75%,并在2小时内完全丧失辅因子活性。在有和没有HUVEC单层存在的情况下对Arg506和Arg306处的切割速率进行测量,结果表明在HUVEC存在时,APC依赖的因子Va HC在Arg506处的切割加速,而在Arg306处的切割则依赖于HUVEC表面的存在。因子Va失活首先是因子Va HC在Arg506处发生初始切割生成一个相对分子质量(M(r))为75,000的产物。在Arg306处的进一步蛋白水解生成一个M(r) 30,000的产物。当向HUVECs中添加蛋白C(0.5 μmol/L)、α-凝血酶(1 nmol/L)和因子Va(20 nmol/L)时观察到APC生成速率为1.56 +/- 0.11 x 10(-14) mol/分钟/细胞。对于原位生成的APC,HUVEC表面上Arg506处的切割之后是Arg306处的切割,分别生成M(r) 75,000和M(r) 30,000的片段。此外,当HUVEC表面存在凝血酶时,观察到因子Va HC衍生出两种新产物:HC通过有限凝血酶蛋白水解加工生成一个M(r) 97,000的片段,该片段再由APC进一步加工生成一个M(r) 43,000的片段。对M(r) 97,000片段的氨基末端序列分析表明,凝血酶切割发生在完整因子Va HC的羧基末端,因为完整的HC以及M(r) 97,000片段具有相同的序列。我们的数据表明,在HUVEC表面上因子Va的失活,无论是由添加APC还是PC活化引发,都遵循一种机制,即首先在Arg506处观察到切割,随后在Arg306处进行第二次切割。后一次切割依赖于HUVEC表面的可用性。因子Va这种失活机制与在合成磷脂囊泡上观察到的类似。